Apellis Aims New Pegcetacoplan Data At Market, Not Regulators

 
• By Alaric DeArment
  
Apellis said it was submitting new, longer-term follow-up data to the FDA for its geographic atrophy drug • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Sensory

More from Therapeutic Category